Elevated levels of M-CSF, sCD14 and IL8 in type 1 Gaucher disease.
In type 1 Gaucher disease, decreased activity of glucocerebrosidase results in accumulation of glucosylceramide in macrophages. Infiltration of liver, spleen and bone marrow by lipid-laden macrophages leads to hepatosplenomegaly, bone lesions and cytopenia. These abnormal macrophages may produce and release macrophage derived factors and cytokines, which could contribute to the pathophysiology of the disease. Whether these cytokines and factors are elevated in Gaucher disease is currently unknown. In 29 type 1 Gaucher disease patients we measured serum levels of the macrophage derived cytokines IL8, IL6, TNFalpha, M-CSF and the monocyte/macrophage activation marker sCD14. These factors were studied in relation to disease severity and during treatment with enzyme supplementation therapy. Most patients showed remarkably elevated levels of M-CSF (2-8 fold) and sCD14 (2-5 fold) as compared to normal controls. Levels of IL8 were elevated in all patients (2-20 fold), whereas levels of IL6 and TNFalpha were normal. There was a significant correlation between severity of the disease as determined by the severity score index (SSI), and M-CSF, sCD14 and IL8 levels. M-CSF and sCD14 levels also correlated with the excess liver and spleen volumes. During treatment with alglucerase, levels of M-CSF and sCD14 declined, but IL8 remained unchanged. The relative reduction in excess liver and spleen volume did not correlate with the relative reduction in M-CSF or sCD14 levels. We conclude that serum levels of M-CSF, sCD14 and IL8 are increased in type 1 Gaucher disease. The biological activities of M-CSF and IL8 may add to the pathophysiology of the disease.
Hollak
C E
CE
Department of Hematology, Academic Medical Centre, Amsterdam, The Netherlands. c.e.hollak@amc.uva.nl
Evers
L
L
Aerts
J M
JM
van Oers
M H
MH
D000293:Adolescent; D000328:Adult; D015703:Antigens, CD / Q000097:blood; D005260:Female; D005776:Gaucher Disease / Q000097:blood* / Q000503:physiopathology / Q000628:therapy; D005962:Glucosylceramidase / Q000627:therapeutic use*; D006801:Humans; D016209:Interleukin-8 / Q000097:blood*; D018950:Lipopolysaccharide Receptors / Q000097:blood*; D008099:Liver / Q000473:pathology; D016173:Macrophage Colony-Stimulating Factor / Q000097:blood*; D008264:Macrophages / Q000276:immunology / Q000473:pathology; D008297:Male; D008875:Middle Aged; D012016:Reference Values; D013154:Spleen / Q000473:pathology
D015703:Antigens, CD; D016209:Interleukin-8; D018950:Lipopolysaccharide Receptors; C070292:alglucerase; D016173:Macrophage Colony-Stimulating Factor; D005962:Glucosylceramidase